<DOC>
	<DOCNO>NCT01015495</DOCNO>
	<brief_summary>The purpose study determine whether injection ranibizumab eye safe well tolerate give subject multiple dos .</brief_summary>
	<brief_title>Ranibizumab Therapy Choroidal Neovascularization ( CNV ) Asociated With Angioid Streaks</brief_title>
	<detailed_description>Choroidal neovascularization hallmark angioid streak , presumably VEGF-driven . Ranibizumab show effective CNV secondary age-related macular degeneration . Therefore , hypothesize ranibizumab may efficacious treatment CNV secondary angioid streak</detailed_description>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Angioid Streaks</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 18 year Angioid streak Subfoveal CNV recent onset follow characteristic Absence subfoveal fibrosis Fibrosis le 25 % lesion Presence blood , subretinal fluid , and/or lipid New onset symptom within 12 week Visual acuity 20/40 20/800 ETDRS chart Prior treatment subfoveal CNV study eye Agerelated macular degeneration Uncontrolled glaucoma High myopia ( &gt; 10.00 D spherical equivalent ) Prior retinal detachment Media opacity prevent adequate view retina Planned cataract surgery next 3 month Current chemotherapy cancer Immunocompromised state Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception . Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial History previous treatment angioid streak</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>angioid streak</keyword>
	<keyword>CNV</keyword>
	<keyword>intra vitreal ranibizumab</keyword>
</DOC>